Skip to content

Study · Systematic review · 2026

6 results

From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.

Alhazmi AM, AlAyoubi F, Mufti RE, Albulushi A

Current problems in cardiology12 Aug 2026

PMID42586458 (opens in a new tab)DOI10.1016/j.cpcardiol.2026.103423 (opens in a new tab)PepBankPUB-42586458
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In dedicated trials in obesity-related HFpEF, semaglutide improved symptoms.

    In plain wordsIn trials of people with obesity-related heart failure, semaglutide improved symptoms.

    Peptide
    Semaglutide
    Outcome
    IncreaseSymptoms in obesity-related HFpEF
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide improves symptoms
    1 context sentence
    Summary · context
    We performed a PRISMA-compliant systematic review with structured narrative evidence synthesis to evaluate pharmacological therapy in obesity-driven HFpEF, searching PubMed/MEDLINE, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP through December 2025.
  2. 02HumanSystematic reviewEfficacy outcome

    In dedicated trials in obesity-related HFpEF, semaglutide improved physical limitations.

    In plain wordsIn trials of people with obesity-related heart failure, semaglutide reduced physical limitations.

    Peptide
    Semaglutide
    Outcome
    IncreasePhysical limitations in obesity-related HFpEF
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide improves symptoms, physical limitations
    1 context sentence
    Summary · context
    We performed a PRISMA-compliant systematic review with structured narrative evidence synthesis to evaluate pharmacological therapy in obesity-driven HFpEF, searching PubMed/MEDLINE, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP through December 2025.
  3. 03HumanSystematic reviewEfficacy outcome

    In dedicated trials in obesity-related HFpEF, semaglutide improved exercise capacity.

    In plain wordsIn trials of people with obesity-related heart failure, semaglutide improved exercise capacity.

    Peptide
    Semaglutide
    Outcome
    IncreaseExercise capacity in obesity-related HFpEF
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide improves symptoms, physical limitations, exercise capacity
    1 context sentence
    Summary · context
    We performed a PRISMA-compliant systematic review with structured narrative evidence synthesis to evaluate pharmacological therapy in obesity-driven HFpEF, searching PubMed/MEDLINE, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP through December 2025.
  4. 04HumanSystematic reviewEfficacy outcome

    In dedicated trials in obesity-related HFpEF, semaglutide reduced body weight.

    In plain wordsIn trials of people with obesity-related heart failure, semaglutide lowered body weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight in obesity-related HFpEF
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide improves symptoms, physical limitations, exercise capacity, and body weight
    1 context sentence
    Summary · context
    We performed a PRISMA-compliant systematic review with structured narrative evidence synthesis to evaluate pharmacological therapy in obesity-driven HFpEF, searching PubMed/MEDLINE, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP through December 2025.
  5. 05HumanSystematic reviewEfficacy outcome

    In obesity-related HFpEF, tirzepatide improved clinical status.

    In plain wordsIn people with obesity-related heart failure, tirzepatide improved clinical status.

    Peptide
    Tirzepatide
    Outcome
    IncreaseClinical status in obesity-related HFpEF
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas tirzepatide extends this signal by improving clinical status and reducing worsening heart failure events.
    1 context sentence
    Summary · context
    We performed a PRISMA-compliant systematic review with structured narrative evidence synthesis to evaluate pharmacological therapy in obesity-driven HFpEF, searching PubMed/MEDLINE, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP through December 2025.
  6. 06HumanSystematic reviewEfficacy outcome

    In obesity-related HFpEF, tirzepatide reduced worsening heart failure events.

    In plain wordsIn people with obesity-related heart failure, tirzepatide reduced events of worsening heart failure.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWorsening heart failure events in obesity-related HFpEF
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    reducing worsening heart failure events.
    1 context sentence
    Summary · context
    We performed a PRISMA-compliant systematic review with structured narrative evidence synthesis to evaluate pharmacological therapy in obesity-driven HFpEF, searching PubMed/MEDLINE, Scopus, Web of Science Core Collection, ClinicalTrials.gov, and WHO ICTRP through December 2025.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.